Akriderm ointment 0.05%, 30 g

Skin diseases amenable to glucocorticosteroid therapy:

- atopic dermatitis;

- allergic contact dermatitis;

- eczema (various forms);

- contact dermatitis (including professional) and other non-allergic dermatitis (including solar and radiation dermatitis);

- reactions to insect bites;

- psoriasis;

- bullous dermatoses;

- discoid lupus erythematosus;

- lichen planus;

- exudative polymorphic erythema;

- pruritus of various etiology.

Outwardly. AkridermЃ ointment is applied in a thin layer to the affected area of ??the skin 2 times a day - in the morning and in the evening, rubbing lightly. On areas with denser skin (for example, elbows, palms and feet), as well as places from which the drug is easily erased, Akriderm ointment can be applied more often. The duration of treatment depends on the effectiveness and tolerability of therapy and is usually no more than 4 weeks. Repeated repetition of therapy is possible during the year.
If clinical improvement does not occur, the diagnosis must be clarified.
In children and in patients with facial skin lesions, the course of treatment should not exceed 5 days.

100 g of ointment contain:
active substance: betamethasone dipropionate in terms of 100% substance - 0.064 g, which is equivalent to 0.05 g of betamethasone;
auxiliary substances: propyl parahydroxybenzoate - 0.05 g, liquid paraffin (liquid paraffin) - 4 g, isopropyl myristate - 1 g, petroleum jelly - up to 100 g.

Hypersensitivity to betamethasone or other components of the drug. Skin tuberculosis, skin manifestations of syphilis, bacterial, fungal, viral (chickenpox, herpes simplex) skin diseases, post-vaccination skin reactions, open wounds, trophic ulcers of the leg, rosacea, vulgar rub, skin cancer, nevus, atheroma, melanoma, hemangioma, xanthoma , sarcoma, lactation period and children under 1 year of age.

With caution
With prolonged use or application to large surfaces: cataracts, diabetes mellitus, glaucoma, tuberculosis.

Trade name of the drug: AkridermЃ

International non-proprietary name:

betamethasone

Dosage form:

topical ointment

Composition
100 g of ointment contain:
active substance: betamethasone dipropionate in terms of 100% substance - 0.064 g, which is equivalent to 0.05 g of betamethasone;
auxiliary substances: propyl parahydroxybenzoate - 0.05 g, liquid paraffin (liquid paraffin) - 4 g, isopropyl myristate - 1 g, petroleum jelly - up to 100 g.

Description
Semi-transparent ointment from white to white with a yellowish sheen.

Pharmacotherapeutic group:

topical glucocorticosteroid

Pharmacological properties
Pharmacodynamics
AkridermЃ is a glucocorticosteroid for external use. It has anti-inflammatory, antiallergic, antiexudative, vasoconstrictor, antipruritic and antiproliferative effects. It inhibits the accumulation of leukocytes, the release of lysosomal enzymes and pro-inflammatory mediators in the focus of inflammation, inhibits phagocytosis, reduces vascular tissue permeability, and prevents the formation of inflammatory edema.
When applied to the surface of the skin, the drug has a quick and strong effect in the focus of inflammation, reducing the severity of objective symptoms (erythema, edema, lichenification) and subjective sensations (itching, irritation, pain).

Pharmacokinetics
With the cutaneous application of the drug in therapeutic doses, the transdermal absorption of the active substance into the blood is very insignificant. The use of occlusive dressings, inflammation and skin diseases increase the transdermal absorption of betamethasone, which may lead to an increased risk of systemic side effects.

Indications for use
Skin diseases amenable to glucocorticosteroid therapy:

- atopic dermatitis;

- allergic contact dermatitis;

- eczema (various forms);

- contact dermatitis (including professional) and other non-allergic dermatitis (including solar and radiation dermatitis);

- reactions to insect bites;

- psoriasis;

- bullous dermatoses;

- discoid lupus erythematosus;

- lichen planus;

- exudative polymorphic erythema;

- pruritus of various etiology.

Contraindications
Hypersensitivity to betamethasone or other components of the drug. Skin tuberculosis, skin manifestations of syphilis, bacterial, fungal, viral (chickenpox, herpes simplex) skin diseases, post-vaccination skin reactions, open wounds, trophic ulcers of the leg, rosacea, vulgar rub, skin cancer, nevus, atheroma, melanoma, hemangioma, xanthoma , sarcoma, lactation and children under 1 year of age.

With caution
With prolonged use or application to large surfaces: cataracts, diabetes mellitus, glaucoma, tuberculosis.

Application during pregnancy and lactation The
safety of external use of glucocorticosteroids in pregnant women has not been established; the prescription of drugs of this group during pregnancy is justified only if the potential benefit to the mother outweighs the possible risk to the fetus. During pregnancy, drugs in this group should not be used in high doses or for a long time.
If it is necessary to use the drug during lactation, it is recommended to stop breastfeeding.

Method of administration and dosage
Outwardly. AkridermЃ ointment is applied in a thin layer to the affected area of ??the skin 2 times a day - in the morning and in the evening, rubbing lightly. On areas with denser skin (for example, elbows, palms and feet), as well as places from which the drug is easily erased, Akriderm ointment can be applied more often. The duration of treatment depends on the effectiveness and tolerability of therapy and is usually no more than 4 weeks. Repeated repetition of therapy is possible during the year.
If clinical improvement does not occur, the diagnosis must be clarified.
In children and in patients with facial skin lesions, the course of treatment should not exceed 5 days.

Side effect
As a rule, it is mild.
With external use of glucocorticosteroids, the following can be observed: itching, burning, irritation, dry skin, folliculitis, hypertrichosis, striae, acne-like rashes ('steroid' acne), hypopigmentation, perioral dermatitis, allergic contact dermatitis. With prolonged use, as well as the use of occlusive dressings, skin maceration, secondary infection, skin atrophy, local hirsutism, telangiectasia, prickly heat, purpura. When applied to large surfaces of the body, mainly in children, systemic side effects of glucocorticosteroids may occur (hyperglycemia, glucosuria, reversible suppression of the adrenal cortex function, manifestation of Itsenko-Cushing's syndrome).
If you experience adverse reactions that are not described in the instructions, you should consult a doctor.

Overdose
Acute overdose is unlikely, however, with excessive or prolonged use of the drug, chronic overdose is possible, accompanied by signs of hypercortisolism: hyperglycemia, glucosuria, reversible suppression of the adrenal cortex function, manifestation of Itsenko-Cushing's syndrome.
Treatment: gradual withdrawal of the drug is recommended and, if necessary, symptomatic treatment.

Interaction with other medicinal products
Interaction of the drug with other medicinal products has not been identified.

Special instructions
Long-term external use of the drug on the skin of the face is not recommended, since the development of rosacea, perioral dermatitis and acne is possible. The course of treatment should not exceed 5 days.
AkridermЃ ointment is not intended for use in ophthalmology. Avoid contact with eyes. If the drug gets on the mucous membranes of the eye, it is possible to develop cataracts, glaucoma, fungal infections of the eye and exacerbation of herpes infection. With prolonged treatment, when the drug is applied to extensive skin surfaces, as well as in the armpits and groin folds, when using occlusive dressings, diapers, systemic absorption of glucocorticosteroids is possible. For children from 1 year old, the drug is prescribed only according to strict indications and under medical supervision, since systemic side effects associated with betamethasone may develop. When using the drug on large surfaces and / or under an occlusive dressing, it is possible to suppress the function of the hypothalamic-pituitary-adrenal system and develop symptoms of hypercortisolism,there may be a decrease in the excretion of growth hormone, an increase in intracranial pressure.
When using the ointment in children from 1 year of age and older, it is necessary to limit the total duration of treatment and exclude measures leading to increased resorption and absorption (warming, fixing and occlusive dressings, diapers).

Influence on the ability to drive vehicles, mechanisms
Does not affect.

Release form
Ointment for external use 0.05%.
15 or 30 g in an aluminum tube. Each tube, together with instructions for use, in a cardboard box.

Storage conditions
At temperatures from 15 to 25 ? C.
Keep out of the reach of children.

Shelf life is
4 years.
Do not use after the expiration date.

Terms of dispensing from pharmacies
Without prescription.